Report Sections

See All Reports

Coronavirus Infections (819) Severe Acute Respiratory Syndrome (567) Infection (472) Pneumonia (366) Communicable Diseases (199) Respiratory Distress Syndrome, Adult (179) Acute Lung Injury (143) Respiratory Distress Syndrome, Newborn (143) Respiratory Insufficiency (132) Syndrome (105) Virus Diseases (90) Pneumonia, Viral (82) Depression (67) Critical Illness (62) Anxiety Disorders (41) Cardiovascular Diseases (36) Emergencies (36) Respiratory Tract Infections (36) Stress, Psychological (31) Hypoxia (30) Inflammation (30) Lung Injury (30) Neoplasms (30) Wounds and Injuries (30) Stress Disorders, Post-Traumatic (29) Thrombosis (28) Diabetes Mellitus (26) Disease (26) Respiratory Tract Diseases (26) Depressive Disorder (25) Stress Disorders, Traumatic (25) Lung Diseases (23) Acute Kidney Injury (22) Disease Progression (22) Mental Disorders (21) Olfaction Disorders (20) Respiration Disorders (20) Burnout, Psychological (19) Thromboembolism (19) Hypertension (18) Embolism (16) Arthritis (15) Blood Coagulation Disorders (15) Hemostatic Disorders (15) Pulmonary Embolism (15) Pulmonary Fibrosis (15) Lung Diseases, Interstitial (14) Stroke (14) Respiratory Aspiration (13) Diabetes Mellitus, Type 2 (12) Dyspnea (12) Fibrosis (12) Influenza, Human (12) Arthritis, Rheumatoid (11) Rheumatic Diseases (11) Venous Thrombosis (11) Burnout, Professional (9) Chronic Pain (9) Cognitive Dysfunction (9) Collagen Diseases (9) Diabetes Mellitus, Type 1 (9) Heart Failure (9) Myocardial Infarction (9) Pneumonia, Ventilator-Associated (9) Pregnancy Complications (9) Problem Behavior (9) Venous Thromboembolism (9) Vitamin D Deficiency (9) Infarction (8) Liver Diseases (8) Lung Diseases, Obstructive (8) Multiple Sclerosis (8) Myocarditis (8) Parasomnias (8) RNA Virus Infections (8) Sclerosis (8) Sepsis (8) Autoimmune Diseases (7) Convalescence (7) Depression, Postpartum (7) Dyssomnias (7) Heart Diseases (7) Hematologic Neoplasms (7) Infertility (7) Inflammatory Bowel Diseases (7) Lymphopenia (7) Pulmonary Disease, Chronic Obstructive (7) Pulmonary Valve Insufficiency (7) Shock (7) Frailty (6) Immunologic Deficiency Syndromes (6) Lung Neoplasms (6) Lupus Erythematosus, Systemic (6) Lymphoma (6) Neurologic Manifestations (6) Obesity (6) Adenoviridae Infections (5) Brain Diseases (5) Brain Injuries (5) Breast Neoplasms (5) Chronic Disease (5) Coronaviridae Infections (5) Cross Infection (5) Delirium (5) Disease Susceptibility (5) Disseminated Intravascular Coagulation (5) Fatigue (5) Feeding and Eating Disorders (5) HIV Infections (5) Immune System Diseases (5) Kidney Diseases (5) Kidney Failure, Chronic (5) Multiple Organ Failure (5) Nervous System Diseases (5) Occupational Stress (5) Parkinson Disease (5) Thrombophilia (5) Toxemia (5) Acquired Immunodeficiency Syndrome (4) Acute Coronary Syndrome (4) Anemia, Sickle Cell (4) Appendicitis (4) Arrhythmias, Cardiac (4) Arthritis, Psoriatic (4) Asymptomatic Diseases (4) Autism Spectrum Disorder (4) Carcinoma (4) Coinfection (4) Colonic Neoplasms (4) Colorectal Neoplasms (4) Coronary Artery Disease (4) Coronary Disease (4) Death (4) Embolism and Thrombosis (4) Fibromyalgia (4) Headache (4) Heart Arrest (4) Leukemia (4) Musculoskeletal Pain (4) Mycobacterium Infections (4) Postoperative Complications (4) Signs and Symptoms, Respiratory (4) Sleep Initiation and Maintenance Disorders (4) Substance-Related Disorders (4) Tuberculosis (4) Ventricular Dysfunction (4) Ventricular Dysfunction, Left (4) Ageusia (3) Alcoholism (3) Asthma (3) Attention Deficit Disorder with Hyperactivity (3) Autistic Disorder (3) Bipolar Disorder (3) Bronchiectasis (3) Cardiomyopathies (3) Chilblains (3) Cystic Fibrosis (3) Deglutition Disorders (3) Digestive System Diseases (3) Dysgeusia (3) Ganglion Cysts (3) Gastrointestinal Diseases (3) Giant Cell Arteritis (3) Head and Neck Neoplasms (3) Hemorrhage (3) Hypersensitivity (3) Hypertension, Pulmonary (3) Leukemia, Lymphocytic, Chronic, B-Cell (3) Measles (3) Melanoma (3) Metabolic Diseases (3) Migraine Disorders (3) Muscle Weakness (3) Myeloproliferative Disorders (3) Myocardial Ischemia (3) Myofascial Pain Syndromes (3) Obesity, Morbid (3) Pancreatic Neoplasms (3) Polymyalgia Rheumatica (3) Pregnancy Complications, Infectious (3) Psoriasis (3) Pulmonary Edema (3) Rare Diseases (3) Renal Insufficiency, Chronic (3) Rheumatic Fever (3) Sjogren's Syndrome (3) Sleep Wake Disorders (3) Spinal Cord Injuries (3) Spondylarthritis (3) Systemic Inflammatory Response Syndrome (3) Taste Disorders (3) Acute Disease (2) Alcohol Drinking (2) Alopecia (2) Amyotrophic Lateral Sclerosis (2) Anorexia (2) Anorexia Nervosa (2) Arteritis (2) Asymptomatic Infections (2) Atrial Fibrillation (2) Atrophy (2) Bacteremia (2) Behcet Syndrome (2) Brain Injuries, Traumatic (2) Carcinoma, Renal Cell (2) Cerebral Palsy (2) Child Development Disorders, Pervasive (2) Cholangiocarcinoma (2) Cholangitis (2) Clinical Deterioration (2) Common Cold (2) Compassion Fatigue (2) Congenital Abnormalities (2) Conjunctivitis (2) Constriction, Pathologic (2) Coronavi (2) Dementia (2) Depressive Disorder, Major (2) Developmental Disabilities (2) Diarrhea (2) Drug-Related Side Effects and Adverse Reactions (2) Encephalitis (2) Endocrine System Diseases (2) Esophageal Neoplasms (2) Eye Diseases (2) Fever (2) Fractures, Bone (2) Fractures, Stress (2) Genetic Predisposition to Disease (2) Glucose Metabolism Disorders (2) Heart Defects, Congenital (2) Hematologic Diseases (2) Hepatitis C (2) Hypothermia (2) Idiopathic Pulmonary Fibrosis (2) Infertility, Male (2) Intestinal Diseases (2) Ischemia (2) Jaundice (2) Leukemia, Lymphoid (2) Liver Cirrhosis (2) Lymphoma, Mantle-Cell (2) Macular Edema (2) Motor Neuron Disease (2) Mouth Diseases (2) Multiple Myeloma (2) Muscular Atrophy (2) Myelodysplastic Syndromes (2) Myositis (2) Neoplasm Metastasis (2) Neoplasms, Plasma Cell (2) Nerve Degeneration (2) Neuroendocrine Tumors (2) Nidovirales Infections (2) Noncommunicable Diseases (2) Obstetric Labor, Premature (2) Oral Manifestations (2) Osteoporosis (2) Overweight (2) Pediatric Obesity (2) Pneumonia, Pneumocystis (2) Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) Premature Birth (2) Psychological Trauma (2) Psychotic Disorders (2) Rectal Neoplasms (2) Renal Insufficiency (2) ST Elevation Myocardial Infarction (2) Sarcopenia (2) Scleroderma, Diffuse (2) Scleroderma, Systemic (2) Seizures (2) Shock, Septic (2) Skin Diseases (2) Sleep Apnea Syndromes (2) Sleep Apnea, Obstructive (2) Stillbirth (2) Suicide (2) Thyroid Diseases (2) Uterine Cervical Neoplasms (2) Vision Disorders (2) Vision, Low (2) Abruptio Placentae (1) Acalculous Cholecystitis (1) Adenocarcinoma (1) Adjustment Disorders (1) Adrenal Insufficiency (1) Agoraphobia (1) Alcohol-Related Disorders (1) Alcoholic Intoxication (1) Alpha 1-Antitrypsin Deficiency (1) Altitude Sickness (1) Alzheimer Disease (1) Amblyopia (1) Anemia, Aplastic (1) Aneurysm (1) Angina Pectoris (1) Ankle Fractures (1) Aortic Valve Stenosis (1) Apnea (1) Arthritis, Juvenile (1) Atherosclerosis (1) Atrioventricular Block (1) Autonomic Nervous System Diseases (1) Bacterial Infections (1) Barotrauma (1) Behavior, Addictive (1) Binge-Eating Disorder (1) Blister (1) Body Weight (1) Body Weight Changes (1) Bradycardia (1) Bronchopulmonary Dysplasia (1) Brucellosis (1) Bulimia (1) Bulimia Nervosa (1) Carcinoma in Situ (1) Carcinoma, Ductal (1) Carcinoma, Ductal, Breast (1) Carcinoma, Hepatocellular (1) Carcinoma, Intraductal, Noninfiltrating (1) Cardiovascular Abnormalities (1) Cataract (1) Cellulitis (1) Central Nervous System Neoplasms (1) Cerebral Hemorrhage (1) Cholangitis, Sclerosing (1) Cholecystitis (1) Cholecystitis, Acute (1) Chronic Traumatic Encephalopathy (1) Ciliary Motility Disorders (1) Cognition Disorders (1) Colitis (1) Colitis, Ulcerative (1) Colonic Diseases (1) Com (1) Communicable Diseases, Emerging (1) Communication Disorders (1) Consciousness Disorders (1) Conversion Disorder (1) Coron (1) Coronavirus Infect (1) Cr (1) Crohn Disease (1) Deafness (1) Death, Sudden, Cardiac (1) Dental Caries (1) Depressive Disorder, Treatment-Resistant (1) Dermatitis (1) DiGeorge Syndrome (1) Diabetes Complications (1) Digestive System Neoplasms (1) Diphtheria (1) Down Syndrome (1) Dyskinesias (1) Dyspareunia (1) Dysphonia (1) Emergen (1) Emergence Delirium (1) Emphysema (1) Endocarditis (1) Endometrial Neoplasms (1) Endometriosis (1) Endophthalmitis (1) Endotoxemia (1) Epilepsy (1) Esophageal and Gastric Varices (1) Eye Infections (1) Facial Pain (1) Facies (1) Familial Mediterranean Fever (1) Fatigue Syndrome, Chronic (1) Femoral Fractures (1) Femoral Neck Fractures (1) Fetal Growth Retardation (1) Fetal Membranes, Premature Rupture (1) Fractures, Closed (1) Gambling (1) Gastroenteritis (1) Gastroesophageal Reflux (1) Gastrointestinal Neoplasms (1) Gestational Weight Gain (1) Glioblastoma (1) Headache Disorders, Secondary (1) Healthcare-Associated Pneumonia (1) Hearing Loss (1) Hearing Loss, Conductive (1) Heart Block (1) Heart Failure, Systolic (1) Hemoglobinopathies (1) Hemophilia A (1) Hepatitis (1) Hereditary Autoinflammatory Diseases (1) Herpes Labialis (1) Herpes Zoster (1) Hoarseness (1) Humeral Fractures (1) Hyp (1) Hyperaldosteronism (1) Hyperglycemia (1) Hyperkinesis (1) Hyperphosphatemia (1) Hyperplasia (1) Hypertension, Pregnancy-Induced (1) Hypertrophy (1) Hypokalemia (1) Hyponatremia (1) Hypotension (1) Hypoventilation (1) Inf (1) Infant, Newborn, Diseases (1) Infe (1) Infec (1) Infecti (1) Infertility, Female (1) Intellectual Disability (1) Intestinal Atresia (1) Intestinal Neoplasms (1) Intracranial Aneurysm (1) Intracranial Hypertension (1) Intracranial Thrombosis (1) Jaundice, Obstructive (1) Joint Diseases (1) Keratoconjunctivitis (1) Kidney Neoplasms (1) Laryngeal Neoplasms (1) Latent Tuberculosis (1) Leukemia, Myeloid, Acute (1) Liver Cirrhosis, Biliary (1) Liver Failure (1) Liver Neoplasms (1) Lymphedema (1) Lymphocytosis (1) Lymphoma, B-Cell (1) Lymphoma, Non-Hodgkin (1) Macrophage Activation Syndrome (1) Macular Degeneration (1) Malnutrition (1) Maternal Death (1) Maxillofacial Injuries (1) Memory Disorders (1) Meningitis (1) Meningitis, Meningococcal (1) Menorrhagia (1) Menstruation Disturbances (1) Metabolic Syndrome (1) Metabolism, Inborn Errors (1) Microvascular Rarefaction (1) Mitochondrial Diseases (1) Mobility Limitation (1) Monoclonal Gammopathy of Undetermined Significance (1) Mood Disorders (1) Mouth, Edentulous (1) Movement Disorders (1) Mucocutaneous Lymph Node Syndrome (1) Multiple Chronic Conditions (1) Muscular Dystrophies (1) Musculoskeletal Diseases (1) Myalgia (1) Mycoses (1) Myocardial Reperfusion Injury (1) Necrosis (1) Needlestick Injuries (1) Neonatal Sepsis (1) Neoplastic Cells, Circulating (1) Nephritis (1) Nervous System Malformations (1) Nervous System Neoplasms (1) Neurocognitive Disorders (1) Neurodegenerative Diseases (1) Neuromuscular Diseases (1) Neuromyelitis Optica (1) Nutrition Disorders (1) Obsessive Behavior (1) Oligospermia (1) Orbital Cellulitis (1) Osteoarthritis (1) Osteoarthritis, Hip (1) Osteoarthritis, Knee (1) Osteochondritis (1) Otitis Media with Effusion (1) Ovarian Neoplasms (1) Pain, Intractable (1) Pancreatitis (1) Paramyxoviridae Infections (1) Paraproteinemias (1) Paresis (1) Parkin (1) Perinatal Death (1) Periodontal Diseases (1) Periodontitis (1) Pharyngeal Diseases (1) Pn (1) Pneumon (1) Pneumonia, Bacterial (1) Pre-Eclampsia (1) Prediabetic State (1) Pregnancy in Diabetics (1) Primary Dysautonomias (1) Prostatic Hyperplasia (1) Protein Deficiency (1) Pseudomonas Infections (1) Psychophysiologic Disorders (1) Puerperal Infection (1) Pulmonary Alveolar Proteinosis (1) Pulmonary Atelectasis (1) Pulmonary Eosinophilia (1) Pulmonary Heart Disease (1) Purpura, Thrombocytopenic, Idiopathic (1) Recurrence (1) Renal Insufficie (1) Reperfusion Injury (1) Resp (1) Respi (1) Respiratory Distress Sy (1) Respiratory Syncytial Virus Infections (1) Retinal Vein Occlusion (1) Rupture (1) Sarcoidosis (1) Scleroderma, Localized (1) Se (1) Shock, Cardiogenic (1) Shoulder Fractures (1) Skin Manifestations (1) Skin Neoplasms (1) Skull Fractures (1) Somatoform Disorders (1) Spondylitis (1) Spondylitis, Ankylosing (1) Sprains and Strains (1) Status Epilepticus (1) Stomach Neoplasms (1) Stress Disorders, Traumatic, Acute (1) Subarachnoid Hemorrhage (1) Suicidal Ideation (1) Superinfection (1) Synovial Cyst (1) Tachycardia (1) Tachycardia, Ventricular (1) Tachypnea (1) Testicular Neoplasms (1) Thalassemia (1) Thoracic Diseases (1) Thrombocytopenia (1) Thrombophlebitis (1) Thrombotic Microangiopathies (1) Tobacco Use Disorder (1) Tonsillitis (1) Torsades de Pointes (1) Tourette Syndrome (1) Tracheal Stenosis (1) Trauma, Nervous System (1) Tuberculosis, Pulmonary (1) Urinary Tract Infections (1) Urogenital Neoplasms (1) Urologic Diseases (1) Uterine Neoplasms (1) Vaginal Neoplasms (1) Vascular Diseases (1) Ventricular Dysfunction, Right (1) Virus (1) Vitamin D Deficie (1) Voice Disorders (1) Vulvar Neoplasms (1) Waldenstrom Macroglobulinemia (1) Weight Gain (1) Weight Loss (1) Yellow Fever (1) beta-Thalassemia (1)

D007251: Influenza, Human

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Navigate: Clinical Trials and HPO


Correlated Drug Terms (24)


Name (Synonyms) Correlation
drug2020 Message directing subjects to information on COVID-19 vaccine safety and efficacy Wiki 0.29
drug278 Artemesia annua Wiki 0.29
drug1190 Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 Wiki 0.29
Name (Synonyms) Correlation
drug1913 MCC IMS Wiki 0.29
drug3602 Video about safety and effectiveness of adult seasonal flu vaccination Wiki 0.29
drug790 Cliniporator Wiki 0.29
drug3404 Thoraxic computed tomography Wiki 0.29
drug3024 Scanning Chest X-rays and performing AI algorithms on images Wiki 0.29
drug1963 Masked Saline Placebo Wiki 0.29
drug4031 qRT-PCR and serology Wiki 0.29
drug284 Artesunate Wiki 0.29
drug1585 IL-12 plasmid Wiki 0.29
drug3577 Vacciantion status in health care workers Wiki 0.29
drug2850 Respiratory infections Wiki 0.29
drug577 CORVax Wiki 0.29
drug1899 Lung CT Wiki 0.29
drug93 ARB Wiki 0.20
drug70 ACE inhibitor Wiki 0.17
drug965 DAS181 Wiki 0.12
drug686 Camostat Mesilate Wiki 0.09
drug482 Blood sample Wiki 0.09
drug1740 Ivermectin Wiki 0.06
drug884 Convalescent Plasma Wiki 0.05
drug2490 Placebo Wiki 0.01

Correlated MeSH Terms (15)


Name (Synonyms) Correlation
D001424 Bacterial Infections NIH 0.29
D012327 RNA Virus Infections NIH 0.10
D012141 Respiratory Tract Infections NIH 0.10
Name (Synonyms) Correlation
D053717 Pneumonia, Ventilator-Associated NIH 0.10
D017563 Lung Diseases, Interstitial NIH 0.08
D018450 Disease Progression NIH 0.06
D003141 Communicable Diseases NIH 0.06
D055370 Lung Injury NIH 0.05
D007239 Infection NIH 0.04
D011024 Pneumonia, Viral NIH 0.03
D014777 Virus Diseases NIH 0.03
D055371 Acute Lung Injury NIH 0.02
D011014 Pneumonia NIH 0.02
D045169 Severe Acute Respiratory Syndrome NIH 0.01
D018352 Coronavirus Infections NIH 0.01

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0011947 Respiratory tract infection HPO 0.10
HP:0006515 Interstitial pneumonitis HPO 0.08
HP:0002090 Pneumonia HPO 0.02

Clinical Trials

Navigate: Correlations   HPO

There are 12 clinical trials


1 Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects

The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination. The investigators plan to recruit male subjects and randomly assign them to four persuasion treatments: three of which vary dimensions of the sender of a medical recommendation (racial concordance, gender concordance, and authority treatments) and one which varies the signal (standard vs. empathetic). Specifically, the investigators will show subjects videos of either Black or white actors/actresses providing scripted information on the flu vaccination. The investigators will randomize the race of the sender and if the subject is Black, also randomize the authority of the sender, with the actor portraying either a doctor or a layperson. Conditional on project funding, subjects assigned to a concordant sender will have the gender of the sender randomized. In addition, the investigators will vary the script used in the experiment between one that acknowledges past injustices (indicated as an empathetic script hereafter) and one that does not (indicated as a standard script hereafter). The investigators will provide subjects a free flu shot coupon and elicit the price at which subjects would be willing to give up this coupon for a cash reward. Lastly, in light of the relevance of vaccination take-up in combating COVID-19 pandemic, the investigators will assess demand for information about a COVID-19 vaccine, with subjects invited to receive results of a safety and efficacy review from a trusted or standard source. The design requires collection of baseline and endline surveys combined with administrative data from pharmacies about coupon redemption. The primary outcomes of interest are posterior beliefs about seasonal flu vaccination, demand and willingness-to-pay (WTP) for a free flu shot coupon, redemption of the coupon, and demand for information about a COVID-19 vaccine.

NCT04160975
Conditions
  1. Flu, Human
  2. Influenza, Human
  3. Covid19
Interventions
  1. Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination
  2. Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy
MeSH:Influenza, Human

Primary Outcomes

Description: The investigators will examine whether a subject updated their beliefs about the risk and benefits of the flu shot after watching the infomercial video.

Measure: Posterior beliefs about the risk/benefits of the flu shot

Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.

Description: The investigators will examine whether subjects invited to receive information on COVID-19 vaccine safety and efficacy from a concordant source exhibited higher demand for such information.

Measure: Demand for information about a COVID-19 vaccine

Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.

Description: The investigators will elicit and measure a subject's flu shot coupon valuations.

Measure: Willingness-to-pay (WTP) for a free flu shot coupon

Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.

Description: The investigators will measure a subject's level of attention and recall from the infomercial video, which could potentially affect their belief updating and decisions on coupon redemption.

Measure: Level of attention and recall from the infomercial video during Baseline survey

Time: This outcome will be assessed during Baseline survey, which takes approximately 20 minutes.

Description: The investigators will measure a subject's level of attention and recall from the infomercial video, which could potentially affect their belief updating and decisions on coupon redemption.

Measure: Level of attention and recall from the infomercial video during Endline survey

Time: This outcome will be assessed during Endline survey, which takes approximately 2 weeks to 3 months after the intervention (depending on the characteristics of the flu season).

Description: The investigators will collect information indicating whether a subject redeemed a flu shot coupon after watching the infomercial video.

Measure: Redemption of said coupon

Time: This outcome will be assessed during the time between Baseline and Endline survey (approximately 2 weeks to 3 months time gap, depending on the characteristics of the flu season).
2 Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling

Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of Influenza and SARS-CoV-2- infection.

NCT04282135
Conditions
  1. Influenza
Interventions
  1. Diagnostic Test: MCC IMS
MeSH:Influenza, Human

Primary Outcomes

Description: Cluster Analysis of MCC IMS spectra will be obtained immediately after sampling

Measure: Cluster Analysis of MCC IMS spectra.

Time: immediatly after sampling
3 A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

NCT04298060
Conditions
  1. Influenza Infection
  2. SAD-RV Infection and COVID-19
Interventions
  1. Drug: DAS181
  2. Drug: Placebo
MeSH:Infection Communicable Diseases Influenza, Human

Primary Outcomes

Description: Percent of subjects who have returned to room air

Measure: Percent of subjects who have returned to room air

Time: 7 days

Description: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1

Measure: Percent change of subjects return to baseline oxygen requirement

Time: 7 days
4 The Benefits of Artificial Intelligence Algorithms (CNNs) for Discriminating Between COVID-19 and Influenza Pneumonitis in an Emergency Department Using Chest X-Ray Examinations

This project aims to use artificial intelligence (image discrimination) algorithms, specifically convolutional neural networks (CNNs) for scanning chest radiographs in the emergency department (triage) in patients with suspected respiratory symptoms (fever, cough, myalgia) of coronavirus infection COVID 19. The objective is to create and validate a software solution that discriminates on the basis of the chest x-ray between Covid-19 pneumonitis and influenza

NCT04313946
Conditions
  1. COVID-19
  2. Pneumonia, Viral
  3. Influenza With Pneumonia
  4. Flu Symptom
  5. Flu Like Illness
  6. Pneumonia, Interstitial
  7. Pneumonia, Ventilator-Associated
  8. Pneumonia Atypical
Interventions
  1. Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images
MeSH:Pneumonia, Ventilator-Associated Influenza, Human Pneumonia, Viral Pneumonia Lung Diseases, Interstitial
HPO:Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pneumonia

Primary Outcomes

Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 positive

Measure: COVID-19 positive X-Rays

Time: 6 months

Description: Number of participants with pneumonitis on Chest X-Ray and COVID 19 negative

Measure: COVID-19 negative X-Rays

Time: 6 months
5 Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.

NCT04367883
Conditions
  1. COVID19
  2. Influenza Vaccination
  3. ACE Inhibitors
  4. ARB
Interventions
  1. Drug: ACE inhibitor
  2. Drug: ARB
MeSH:Influenza, Human

Primary Outcomes

Description: exitus vs hospital output

Measure: hospital output

Time: from March 1, 2020.

Secondary Outcomes

Description: lenght of the hospital stay

Measure: hospital stay

Time: From March 1, 2020.
6 Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients

The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to compare the radiological patterns found in patients with COVID-19 and influenza H1N1. The secondary aims of this study will assess the association between the radiological CT pattern and the need for invasive mechanical ventilation and mortality within the first 28 days of intensive care unit admission.

NCT04497311
Conditions
  1. SARS-CoV-2
  2. Covid19
  3. H1N1 Influenza
  4. Computed Tomography
Interventions
  1. Diagnostic Test: Thoraxic computed tomography
MeSH:Influenza, Human

Primary Outcomes

Description: Lung CT radiological patterns associated with COVID-19 or Influenza H1N1

Measure: Radiological findings

Time: 24 hours

Secondary Outcomes

Description: Intrahospital and overall survival at 28 days from hospital admission.

Measure: Survival

Time: 28 days
7 Pulmonary Tomographic Findings in COVID-19 and Influenza H1N1 Patients at IMSS Guanajuato

The investigators decided to conduct a longitudinal study that compares the pulmonary tomographic patterns found in patients with viral pneumonia (i.e. influenza H1N1 and SARS-CoV-2) at a regional hospital. The primary aim of this study is to evaluate the association between the radiological CT pattern and the need for invasive mechanical ventilation. A secondary aim is to assess the mortality within the first 28 days of intensive care unit admission.

NCT04499378
Conditions
  1. Covid19
  2. Influenza A H1N1
  3. Intubation Complication
  4. Morality
  5. Lung Injury, Acute
Interventions
  1. Diagnostic Test: Lung CT
MeSH:Influenza, Human Lung Injury Acute Lung Injury

Primary Outcomes

Description: Need for oral intubation within the first 10 days.

Measure: Oral intubation

Time: 10 days

Secondary Outcomes

Description: 28-day survival analysis using the Kaplan Meyer and Cox regression models.

Measure: Survival

Time: 28 days
8 Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Multicentre Academic Prospective Cohort Study in Nursing Home During the Winter Season 2020-2021

Background: Each Belgian winter season is characterized by a wave of influenza like and respiratory symptoms. Especially, the elderly people are more vulnerable to be infected by influenza, but also RSV. The recent COVID-19 pandemic and eventually a next wave, will increase the prevalence of influenza like and respiratory symptoms. Method: A multicentre non-commercial cohort study will be conducted in nursing home staff and residents during the Winter season 2020-2021. Objectives: Primary objective is the difference in incidence of influenza like and respiratory symptoms between cases (cases have evidence of past infection with SARS-CoV-2, referred to as Covid +) and controls (controls have no evidence of previous infection and are referred to as Covid -). The primary outcome analysis as well as the secondary outcome analyses will use two strata: nursing home staff and nursing home residents. The secondary objectives are the difference in incidence of COVID-19, influenza, RSV infections confirmed by PCR between cases and controls, to define a correlate of protection in the covid + group against re-infection with SARS-CoV-2 based on the study of the pre-existing antibody profile (antigen specificity, antibody type and antibody level) at the time of re-exposure. A multiplex assay will be used to assess the antibody profile. Finally, to study the COVID-19 disease severity (7 point WHO ordinal scale, this includes a.o. hospitalisation, mechanical ventilation need and ICU admission, mortality) based on the presence/absence of pre-existing antibodies and the pre-existing antibody profile. For other respiratory infections we will study the need for hospitalization and mortality.

NCT04527614
Conditions
  1. Influenza, Human
  2. SARS Virus
  3. COVID-19
  4. Espiratory Tract Infections
Interventions
  1. Diagnostic Test: qRT-PCR and serology
MeSH:Infection Communicable Diseases Respiratory Tract Infections Influenza, Human
HPO:Respiratory tract infection

Primary Outcomes

Description: This study will assess the time to the occurrence of influenza-like illness (ILI) or acute respiratory infection (ARI) in subjects previously COVID+ compared to subjects known as COVID- (controls), more specifically subjects will belong to two subgroups: nursing home residents (65+) and nursing home staff (18-65y). COVID+ is defined as a past SARS-CoV-2 infection.

Measure: Time to occurrence of ILI and ARI both in participants previously exposed to SARS-COV-2 and controls

Time: up to 8 months

Secondary Outcomes

Measure: Number of patients with ILI or ARI, diagnosed with COVID-19, influenza, RSV

Time: up to 8 months

Measure: Validation of (SimplySpiro) to replace nasopharyngeal swabs

Time: up to 8 months

Measure: Identify the antibody characteristics in participants with reinfection with SARS-CoV-2

Time: up to 8 months

Description: Disease severity will be measured by hospitalization and mortality

Measure: Correlation of the pre-existing antibody characteristics for COVID-19 with disease severity.

Time: up to 8 months

Measure: Correlation of the level of neutralization antibodies against influenza subtypes with protection against influenza reinfection

Time: up to 8 months
9 Evaluation of Cell-mediated and Humoral Immunity Following COVID-19 in Pregnancy

The proposed study is designed to investigate if and how pregnant women infected with Coronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. In December 2019, a group of people in Wuhan, China presented with symptoms of a pneumonia of an unknown cause that led to the discovery of a new coronavirus called COVID-19. COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deaths as of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and 41,662 deaths as of 13th June 2020. In humans, this infection primarily involves the upper part of the lungs, but it can also affect other organs. It causes mild symptoms in the majority of people affected but some people can have severe infections, with some even requiring critical care in hospital. During Severe acute respiratory syndrome (SARS), a previous coronavirus epidemic, pregnant women were disproportionately affected with severe illness. Understanding how the immune system responds long-term to this infection may hold the key to developing better vaccines and efficient treatment plans. Specialised immunity develops when individuals are infected by this and other viruses. The investigators of this study propose that, in pregnancy, this specialised immunity may not behave effectively. This may affect their ability to develop long lasting immunity and make them more vulnerable to re-infection. In this study, the investigators aim to recruit patients across 6 groups including COVID-19 newly infected pregnant women, and people with differing illness severity, mild to moderate, severe/critical, no infection (controls), as well as pregnant women with influenza and those receiving influenza vaccine. The study team will compare COVID-19 in pregnancy with non-pregnant infected and with influenza infected and vaccinated pregnant women. The study team will consent patients in all of these groups to provide a series of blood samples at different time points in a 12-month period.

NCT04568044
Conditions
  1. COVID-19
  2. Pregnancy Related
  3. Influenza, Human
Interventions
  1. Procedure: Blood sample
MeSH:Influenza, Human

Primary Outcomes

Description: Devise a flow cytometry panel to phenotype B cells.

Measure: Phenotyping antibody secreting cells (ASCs) and memory B cells during COVID-19 infection, and post recovery.

Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point.

Description: B cell ELISpot assay and quantify Immunoglobulin A (IgA) and IgG using Enzyme-linked immunosorbent assay (ELISA) from plasma and/or serum from COVID-19 recovered individuals.

Measure: Quantification of SARS-CoV-2 specific IgG production by memory B cells to measure long-lasting immune protection against re-infection.

Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection. Group C: 1 day. 1 time point.

Secondary Outcomes

Description: Use real-time PCR (RT-PCR) and nested PCR to detect SARS-CoV-2 viral load

Measure: Quantification of SARS-COV-2 viral load using PCR.

Time: Groups A, B, D: at 7-14 days and during recovery phase. Group C: 1 day. 1 time point.

Description: Devise a flow cytometry panel to phenotype cTFH cells.

Measure: Immuno-phenotype circulatory T follicular helper cells (cTFH) cells post SARS-CoV-2 infection.

Time: Groups A, B, D: at 7-14 days post infection or vaccination. Group C: 1 day. 1 time point.

Description: Use a combination of flow cytometry, enzyme-linked immunospot (ELISpot) assays, and DNA/RNA analysis.

Measure: Investigating T cell mediated immune function post COVID-19

Time: Groups A, B, D: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point.

Description: Parameters including antibody titres, cTFH and memory B cell and ASC proportions, and T cell function will be compared between COVID-19 infected, and influenza infected and vaccinated pregnant women.

Measure: In pregnancy, comparing antibody production, and immune phenotype and function (as outlined above) between COVID-19 infection, and influenza infected or vaccinated.

Time: Groups A, B, D, E and F: Between 4 months with a minimum of 2 time points (i.e. 8 and 12 months), and 12 months with a maximum 5 time points (i.e. 7-14 days, then 1, 4, 8, 12 months) post infection/vaccination. Group C: 1 day. 1 time point.
10 Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of the University Clinical Center of the Medical University of Warsaw

The study will be conducted in the UCKWUM teaching hospital in Warsaw between 2020 and 2022. The study group will be comprised of UCKWUM healthcare professionals All employees willing to participate in the study will receive an anonymous questionnaire on attitudes towards influenza vaccination . We will distribute information posters of the National Programme for Combating Influenza as part of the educational programme. In order to increase the effectiveness of the educational campaign, we will also send information e-mails, using the internal hospital e-mail system and conduct a series of online training courses to present the latest international reports on influenza vaccinations among health care professionals [CITATION Abr10 \l 1045]. Considering the fact that lack of time [CITATION Kus11 \l 1045] is the most common reason for not getting vaccinated against influenza among healthcare professionals, we will provide this group with an opportunity to receive free influenza vaccination during working hours at the UCKWUM hospital. Information about the possibility of vaccination will be provided in the form of e-mails (mailings) to hospital employees (internal hospital e-mail system), letters of information submitted to the offices of individual departments, and information posters. The effectiveness of the educational programme will be assessed by re-administering the anonymous questionnaires after the influenza season, also by means of internal hospital e-mail system.

NCT04569019
Conditions
  1. Vaccnation in HCW
Interventions
  1. Other: Vacciantion status in health care workers
MeSH:Influenza, Human

Primary Outcomes

Measure: Assesment of vaccination indeks in the hsopital by using questionare

Time: 3 years
11 Predicting Severity and Disease Progression in Influenza-like Illness

Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell. Influenza ('flu') is one of the most common causes of lung infection. Seasonal flu affects between 10% and 46% of the population each year and causes around 12 deaths in every 100,000 people infected. In addition, both influenza and coronaviruses have caused pandemics in recent years, leading to severe disease in many people. Although flu vaccines are available, these need to change every year to overcome rapid changes in the virus and are not completely protective. This study aims to find and develop predictive tests to better understand how and when flu-like illness progresses to more severe disease. This may help to decide which people need to be admitted to hospital, and how their treatment needs to be increased or decreased during infection. The aim is to recruit 100 patients admitted to hospital due to a respiratory infection. It is voluntary to take part and participants can choose to withdraw at any time. The study will involve some blood and nose samples. This will be done on Day 0, Day 2 and Discharge from hospital, and an out-patient follow-up visit on Day 28. The data will be used to develop novel diagnostic tools to assist in rational treatment decisions that will benefit both individual patients and resource allocation. It will also establish research preparedness for upcoming pandemics.

NCT04664075
Conditions
  1. Influenza
  2. SARS (Severe Acute Respiratory Syndrome)
  3. Respiratory Viral Infection
  4. Respiratory Tract Infections
  5. Infection, Bacterial
  6. Infection Viral
  7. Covid19
  8. RNA Virus Infections
Interventions
  1. Biological: Respiratory infections
MeSH:Infection Communicable Diseases Respiratory Tract Infections Bacterial Infections Influenza, Human Virus Diseases Severe Acute Respiratory Syndrome Coronavi Coronavirus Infections RNA Virus Infections Disease Progression
HPO:Respiratory tract infection

Primary Outcomes

Description: The identity of pathological organisms associated with influenza-like illness (including respiratory viruses and bacteria) will be obtained from the patient's medical record

Measure: Describe the aetiology of influenza-like illness in hospitalised adults

Time: Day 0 to Day 28

Description: The following data will be collected from the patient's medical record. At enrolment, data will consist of: past medical history, clinical signs and symptoms relating to this admission, vital signs (pulse rate, blood pressure, temperature, oxygen saturation), demographics, drug history, laboratory results including diagnostic microbiological tests and interventions. Data collection on Day 28 will consist of clinical diagnosis at discharge, any febrile illness in the 7 days preceding the visit, mortality and complications between Day 0 and 28.

Measure: Describe the clinical outcomes of influenza-like illness in hospitalised adults

Time: Day 0 to Day 28

Secondary Outcomes

Description: Cytokine levels (in pg/mL) will be measured in plasma and nasal lining fluid samples by MesoScale Discovery

Measure: Identify changes in cytokine levels during influenza-like illness in hospitalised adults

Time: Day 0 to Day 28
12 Assessment of Unsupervised Self-Collected Saliva Sample Compared to Clinician CollectedSaliva Sample and Clinician Collected Anterior Nares Sample in a COVID-19 and Influenza A/Influenza B Screening Program

We are trying to see whether a self-collected saliva swab in the home setting is as good as or better than a study clinician-collected anterior nose swab in evaluating whether you are positive for COVID-19 or Influenza A/Influenza B. You may have no symptoms, so you may be positive and capable of spreading the infection to others and you don't know it. Knowing whether you are positive is important because you would have to quarantine and not go out to prevent spreading the infection to others.

NCT04681950
Conditions
  1. Subjects Possibly Exposed to COVID-19
MeSH:Influenza, Human

Primary Outcomes

Description: Samples will be collected by the patient and a HCP

Measure: Matching results from different collection types

Time: 3 days from the time of collection

HPO Nodes


HPO

Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


HPO Nodes


Reports

Data processed on January 01, 2021.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports   MeSH Reports   HPO Reports  

Interventions

4,818 reports on interventions/drugs

MeSH

706 reports on MeSH terms

HPO

306 reports on HPO terms

All Terms

Alphabetical index of all Terms

Google Colab

Python example via Google Colab Notebook